Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:50743
Name mature T-cell and NK-cell lymphoma
Definition A non-Hodgkin lymphoma that has_material_basis_in mature T lymphocytes and natural killer cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma mature T-cell and NK-cell lymphoma


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
JAK3 A572V Tofacitinib mature T-cell and NK-cell lymphoma sensitive detail...
Unknown unknown DS-3201b mature T-cell and NK-cell lymphoma not applicable detail...
Unknown unknown Tenalisib mature T-cell and NK-cell lymphoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02232516 Phase II Lenalidomide + Romidepsin Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma Recruiting
NCT02342782 Phase I Carmustine + Cytarabine + Etoposide + Melphalan + Yttrium Y 90 Basiliximab Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma Active, not recruiting
NCT02567656 Phase I Tenalisib Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma Completed
NCT02588651 Phase II Brentuximab vedotin A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Recruiting
NCT02973113 Phase I EB-VST cells + Nivolumab Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE) Active, not recruiting
NCT02974647 Phase II Ruxolitinib Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma Recruiting
NCT02978625 Phase II Nivolumab + Talimogene laherparepvec Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting
NCT03049449 Phase I ATLCAR.CD30 cells Cyclophosphamide + Fludarabine T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Recruiting
NCT03075553 Phase II Nivolumab Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Terminated
NCT03081910 Phase I CD5 CAR T cells Cyclophosphamide + Fludarabine Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) Recruiting
NCT03113500 Phase II Etoposide Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone Doxorubicin Cyclophosphamide Prednisone Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma Recruiting
NCT03372057 Phase II Duvelisib A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) Recruiting
NCT03586024 Phase Ib/II Pembrolizumab Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL) Active, not recruiting
NCT03719105 Phase I Pembrolizumab Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Pralatrexate + Prednisone Calaspargase pegol-mknl + Dexamethasone + Etoposide + Ifosfamide + Methotrexate Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma Recruiting
NCT03728972 Phase II Pembrolizumab Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type Recruiting
NCT04233697 Phase I Copanlisib + Romidepsin Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma Withdrawn
NCT04447027 Phase I Azacitidine + Dexamethasone + Lenalidomide + Romidepsin A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies Not yet recruiting